Nuwellis Q1 net sales $2.4M (+26% YoY); gross margin 70.1%; net loss $4.3M

Nuwellis, Inc.

Net sales $2.4M, up 26% from $1.9M YoY; gross margin 70.1% (improved 14% YoY).
Net loss $4.3M; operating expenses $6.0M (up from $4.1M) due to sales headcount.
Cash $2.2M, no debt as of March 31, 2026.
Acquired Rendiatech (kidney-function monitoring); appointed Carisa Schultz as CFO.
Appointed Martin J. Emerson and David A. McDonald to Board; new patents and TX territory.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nuwellis, Inc. reported the first quarter ended March 31, 2026 results: revenue $2.4 million, net income approximately $4.3 million.

Period: the first quarter ended March 31, 2026
Revenue: $2.4 million
Net income: approximately $4.3 million
Result: reported results

Exact text from the filing

for patients with cardiorenal conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter and Recent Highlights: • Net sales were $2.4 million, a 26% increase compared to the prior-year period • Gross margin improved to 70.1%, reflecting improved pricing, product mix, and the transition to contract manufacturing •

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuwellis, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-020805

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.